Abbott Laboratories has settled a patent fight with Teva Pharmaceutical Industries Ltd., maker of a generic version of TriCor, Abbott's best-selling branded cholesterol drug. The settlement will leave alive claims that North Chicago, Ill.-based Abbott violated antitrust laws through "market conversions," or moves to switch users from one formulation of the drug to another to dodge competition from generic-drug makers. "Patent litigation has been amicably resolved and the parties have agreed to dismiss the patent claims," said Jennifer Smoter, a spokeswoman for Abbott. She said this will allow Israel-based Teva to go ahead, if it wishes, with the launch of a generic TriCor.

Posted by GEN-ERIC at 12:00:50 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/258

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)